On September 6^th, 2024, representatives from Celltrion, a Korean biopharmaceutical company, visited the Shanghai Operations Management Center of Hasten Biopharmaceutical Co.,Ltd  (referred to as “Hasten”).

[June 28th, 2024] Hasten Biopharmaceutical Co., Ltd. (referred to as “Hasten”) announced today that it has successfully acquired the asset rights of 14 branded products across Pan-Asia countries and regions from Celltrion, a Korean biopharmaceutical company.

On May. 17th, 2024, Hasten Biopharmaceutical Limited Co., Ltd. (hereinafter as Hasten) announced that the clinical trial application (IND) for Lerodalcibep(hereinafter as the code：HST101), a novel third-generation PCSK9 inhibitor, has been approved by the Center for Drug Evaluation(CDE) of the National Medical Products Administration (NMPA) for the treatment of patients with hypercholesterolemia. The Company will accelerate domestic clinical trial preparations and initiate recruitment of subjects with hypercholesterolaemia.

On 29th, March, Hasten Biopharmaceutical Co., Ltd (hereinafter referred to as "Hasten") signed a strategic cooperation agreement with Naxions on the "Hasten&Naxions Innovation Project". According to the agreement, Naxions will assist in promoting the accessibility of Hasten's high-quality products in specific markets through its multi-dimensional digital model to benefit more patients and jointly create greater social health value.

On December 19, 2023, Hasten’s CEO Summer XIA, Vice President and Head of Commercial Excellence Hanson Zheng and other senior leaders from Hasten visited Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. (CR Gosun), and signed a MOU for the deep collaboration with CR Gosun.

On December 14, 2023, Hasten Biopharmaceutical Co., Ltd announced that it will enter into a strategic business partnership with Apeloa Pharmaceutical Co., Ltd.